[Novel targets in the treatment of patients with atrial fibrillation: from elimination of symptoms to improvement of clinical outcomes].
V A
VA
Sulimov
D000638:Amiodarone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D017115:Catheter Ablation; D002986:Clinical Trials as Topic; D000077764:Dronedarone; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D008991:Monitoring, Physiologic; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000592:standards; D055502:Secondary Prevention; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D000077764:Dronedarone; D000638:Amiodarone